Keros Therapeutics, Inc. (NASDAQ: KROS)

Keros Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing therapeutics that modulate the transforming growth factor beta, or TGFβ, superfamily of proteins. The company’s approach centers on understanding how TGFβ ligands regulate tissue growth, repair and homeostasis in skeletal muscle, bone, adipose tissue, heart and blood. Its lead product candidate, rinvatercept (KER-065), is designed to inhibit myostatin and activin A to increase muscle mass and strength and is being advanced for Duchenne muscular dystrophy and amyotrophic lateral sclerosis. Another key candidate, elritercept (KER-050), is an engineered ligand trap that aims to boost red blood cell and platelet production by inhibiting select TGFβ signals involved in ineffective hematopoiesis, targeting myelodysplastic syndromes and myelofibrosis. The firm leverages its deep expertise in TGFβ biology to build a pipeline of protein therapeutics with potential disease modifying effects.

Keros Therapeutics currently generates revenue primarily through collaboration and licensing agreements rather than product sales. In December 2024 the company entered into an exclusive license agreement with Takeda Pharmaceuticals U. S. A., Inc. granting Takeda rights to develop, manufacture and commercialize elritercept worldwide excluding mainland China, Hong Kong and Macau, which triggered an upfront payment of $200 million and a $10 million milestone after dosing the first patient in a Phase 3 trial. An earlier agreement with Hansoh (Shanghai) Healthtech Co., Ltd. provides similar rights for the Greater China region and contributed an $18 million upfront payment plus potential milestones and royalties. These arrangements supply the bulk of the company’s income while it advances its clinical programs.

Within the biopharmaceutical industry Keros Therapeutics occupies a niche as a specialist in TGFβ pathway modulation, competing with larger firms that also pursue muscle and blood disorder treatments such as Roche, Novartis, Sarepta Therapeutics and CRISPR based gene therapy companies. Its competitive advantage lies in the proprietary discovery platform that generates engineered ligand traps designed to selectively inhibit specific TGFβ ligands while sparing others, a capability supported by extensive preclinical data and a management team with prior experience at Acceleron Pharma and Wyeth. The company’s collaborations with Takeda and Hansoh validate its science and provide non dilutive funding, allowing it to retain full ownership of its neuromuscular assets while sharing commercialization risk for its hematology candidate.

The company’s intended customers are patients suffering from severe neuromuscular and hematologic diseases, including individuals with Duchenne muscular dystrophy, amyotrophic lateral sclerosis, myelodysplastic syndromes and myelofibrosis, as well as the healthcare providers and payers that serve these populations. While no commercial product is yet available, the firm’s licensing partners such as Takeda and Hansoh act as interim customers by providing milestone payments and funding for clinical development. Success in clinical trials will translate into demand from hospitals, infusion centers and specialty clinics that treat the targeted rare diseases.